Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox
← Back to News

Zepbound and Foundayo telehealth access via Hims & Hers

J

By João L. Carapinha

November 9, 2026

Clinical Practice
Zepbound and Foundayo telehealth access

Zepbound and Foundayo telehealth access widens under a new agreement between Eli Lilly and Hims & Hers Health, announced on 6 November 2026. Eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform can pay the same self-pay prices available to any patient, without leaving the platform. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.

How Zepbound and Foundayo telehealth access works

A patient completes a consultation, and the provider decides whether a prescription is appropriate. If it is, the medicine ships directly to the patient’s home. Hims & Hers says its weight-loss membership includes 24/7 access to a care team, nutrition guidance and regular clinical check-ins.

Hims & Hers has never offered compounded copies of Lilly’s GLP-1s and has committed not to in the future. The companies also committed to protecting independent clinical decision-making, so providers on the platform keep prescribing the treatment they judge right for each patient.

Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, said Lilly is always looking for new ways to help more people get the medicines they need, and that “means meeting patients where they already are.”

Why it matters

The release puts Foundayo, the daily oral medicine, and Zepbound, the injectable, on one consumer platform aimed at adults with obesity who already seek care through telehealth. It gives self-pay prices and does not mention insurance or payer coverage. Our earlier piece on DTC telehealth partnerships tracks the same model of pharma firms selling through digital platforms, and our look at direct-to-consumer pharmaceutical access covers the NovoCare version.

Source: Eli Lilly and Company news release, 6 November 2026

Let Google know we are your trusted source.

Add our editorial as a preferred source in your search results.

Trust this Source